Spire Wealth Management increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 40.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 81,351 shares of the medical research company's stock after purchasing an additional 23,278 shares during the quarter. Spire Wealth Management's holdings in Edwards Lifesciences were worth $6,045,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. AustralianSuper Pty Ltd acquired a new position in shares of Edwards Lifesciences during the 4th quarter worth about $168,519,000. Nordea Investment Management AB boosted its position in shares of Edwards Lifesciences by 1,224.1% during the 4th quarter. Nordea Investment Management AB now owns 1,610,412 shares of the medical research company's stock worth $123,261,000 after acquiring an additional 1,488,791 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Edwards Lifesciences by 9.2% during the 3rd quarter. Wellington Management Group LLP now owns 16,434,401 shares of the medical research company's stock worth $1,138,575,000 after acquiring an additional 1,390,427 shares in the last quarter. FMR LLC boosted its position in shares of Edwards Lifesciences by 61.1% during the 3rd quarter. FMR LLC now owns 3,111,385 shares of the medical research company's stock worth $215,557,000 after acquiring an additional 1,179,637 shares in the last quarter. Finally, J.P. Morgan Private Wealth Advisors LLC acquired a new position in shares of Edwards Lifesciences during the 3rd quarter worth about $60,971,000. 79.46% of the stock is owned by institutional investors and hedge funds.
Edwards Lifesciences Stock Performance
NYSE EW traded down $0.16 on Monday, hitting $85.09. 2,438,926 shares of the company's stock were exchanged, compared to its average volume of 3,757,333. The company has a debt-to-equity ratio of 0.08, a current ratio of 3.75 and a quick ratio of 2.67. The firm's 50-day moving average price is $90.06 and its two-hundred day moving average price is $79.58. Edwards Lifesciences Co. has a fifty-two week low of $60.57 and a fifty-two week high of $96.12. The firm has a market cap of $51.28 billion, a price-to-earnings ratio of 36.68, a P/E/G ratio of 3.59 and a beta of 1.10.
Edwards Lifesciences (NYSE:EW - Get Free Report) last released its earnings results on Thursday, April 25th. The medical research company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 22.86% and a net margin of 23.01%. The company had revenue of $1.60 billion for the quarter, compared to analysts' expectations of $1.58 billion. On average, research analysts expect that Edwards Lifesciences Co. will post 2.77 EPS for the current year.
Wall Street Analyst Weigh In
Several research analysts have recently issued reports on the company. Wells Fargo & Company upped their price objective on Edwards Lifesciences from $94.00 to $99.00 and gave the stock an "overweight" rating in a research report on Friday, April 26th. Piper Sandler boosted their target price on Edwards Lifesciences from $85.00 to $88.00 and gave the company a "neutral" rating in a report on Friday, April 26th. Citigroup boosted their target price on Edwards Lifesciences from $90.00 to $98.00 and gave the company a "neutral" rating in a report on Wednesday, April 3rd. Morgan Stanley boosted their target price on Edwards Lifesciences from $95.00 to $103.00 and gave the company an "overweight" rating in a report on Thursday, March 21st. Finally, Evercore ISI reduced their target price on Edwards Lifesciences from $92.00 to $89.00 and set an "in-line" rating for the company in a report on Friday, April 26th. One analyst has rated the stock with a sell rating, six have issued a hold rating and eleven have issued a buy rating to the company. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and a consensus target price of $92.71.
Check Out Our Latest Report on Edwards Lifesciences
Insider Activity at Edwards Lifesciences
In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company's stock, valued at approximately $3,390,542.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Donald E. Bobo, Jr. sold 11,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 13th. The stock was sold at an average price of $85.83, for a total value of $944,130.00. Following the completion of the transaction, the vice president now directly owns 39,503 shares of the company's stock, valued at approximately $3,390,542.49. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Scott B. Ullem sold 7,255 shares of the firm's stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $85.59, for a total value of $620,955.45. Following the transaction, the chief financial officer now directly owns 19,074 shares of the company's stock, valued at approximately $1,632,543.66. The disclosure for this sale can be found here. Insiders sold 237,749 shares of company stock valued at $20,920,934 in the last ninety days. Corporate insiders own 1.27% of the company's stock.
About Edwards Lifesciences
(
Free Report)
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.
Further Reading
Before you consider Edwards Lifesciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edwards Lifesciences wasn't on the list.
While Edwards Lifesciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
